Vistagen gets FDA feedback on Phase 3 social anxiety drug

Vistagen held a Type C meeting with the FDA to discuss the development of fasedienol for social anxiety disorder. The agency provided constructive feedback on the use of the LSAS and recommended interim assessments to evaluate longer-term functional improvements.